Indirect treatment comparison and cost-minimization analysis of
riociguat versus selexipag in patients with pulmonary arterial
hypertension

J 2022

Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension

ORNSTOVA, Eva, Jan TUZIL, Katerina CHADIMOVA, Tomas MLCOCH, Tomáš DOLEŽAL et. al.

Základní údaje

Originální název

Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension

Autoři

ORNSTOVA, Eva (203 Česká republika), Jan TUZIL (203 Česká republika), Katerina CHADIMOVA (203 Česká republika, garant), Tomas MLCOCH (203 Česká republika) a Tomáš DOLEŽAL (203 Česká republika, domácí)

Vydání

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, ABINGDON, TAYLOR & FRANCIS LTD, 2022, 1473-7167

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.300

Kód RIV

RIV/00216224:14110/22:00128266

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1080/14737167.2022.2126833

UT WoS

000861698100001

Klíčová slova anglicky

Bucher indirect comparison; cost-minimization analysis; riociguat; selexipag; pulmonary arterial hypertension; systematic review

Štítky

14110516, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2023 11:02, Mgr. Tereza Miškechová

Anotace

V originále

Objectives The comparative efficacy between riociguat and selexipag in patients with pulmonary arterial hypertension (PAH) has never been described in literature. Our aim was to prepare indirect treatment comparison (ITC) to evaluate the cost-effectiveness of riociguat in Czechia. Methods A systematic literature review identified two relevant trials with comparable endpoints to inform a Bucher ITC of relative and absolute effects. Given the comparable efficacy of riociguat and selexipag, a cost-minimization analysis (CMA) was conducted. Results A Bucher ITC provided evidence for the comparable relative efficacy of riociguat defined as the odds of unimproved functional class III 0.761 (95% CI 0.372 to 1.558; p = 0.455) compared to selexipag and a comparable absolute efficacy defined as a difference in the 6-minute walking distance of 10.560 meters (95% CI -10.692 to 31.812; p = 0.330). The CMA identified riociguat as the cost-saving therapy. Conclusions Switching to riociguat represents the cost-saving therapy for PAH patients who were inadequately compensated with the PDE5i+ERA therapy. Consequently, riociguat has been introduced to the list of reimbursed medicines in Czechia from October 2021. Based on two global trials, we prepared the first indirect treatment comparison followed with CMA of these therapies that may improve future decision-making for PAH indications.

Citovat

ORNSTOVA, Eva, Jan TUZIL, Katerina CHADIMOVA, Tomas MLCOCH a Tomáš DOLEŽAL. Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. ABINGDON: TAYLOR & FRANCIS LTD, 2022, roč. 22, č. 8, s. 1269-1275. ISSN 1473-7167. Dostupné z: https://dx.doi.org/10.1080/14737167.2022.2126833.

@article{2249588,
   author = {Ornstova, Eva and Tuzil, Jan and Chadimova, Katerina and Mlcoch, Tomas and Doležal, Tomáš},
   article_location = {ABINGDON},
   article_number = {8},
   doi = {http://dx.doi.org/10.1080/14737167.2022.2126833},
   keywords = {Bucher indirect comparison; cost-minimization analysis; riociguat; selexipag; pulmonary arterial hypertension; systematic review},
   language = {eng},
   issn = {1473-7167},
   journal = {EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH},
   title = {Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension},
   url = {https://www.tandfonline.com/doi/abs/10.1080/14737167.2022.2126833?journalCode=ierp20},
   volume = {22},
   year = {2022}
}

TY  - JOUR
ID  - 2249588
AU  - Ornstova, Eva - Tuzil, Jan - Chadimova, Katerina - Mlcoch, Tomas - Doležal, Tomáš
PY  - 2022
TI  - Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension
JF  - EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
VL  - 22
IS  - 8
SP  - 1269-1275
EP  - 1269-1275
PB  - TAYLOR & FRANCIS LTD
SN  - 14737167
KW  - Bucher indirect comparison
KW  - cost-minimization analysis
KW  - riociguat
KW  - selexipag
KW  - pulmonary arterial hypertension
KW  - systematic review
UR  - https://www.tandfonline.com/doi/abs/10.1080/14737167.2022.2126833?journalCode=ierp20
N2  - Objectives The comparative efficacy between riociguat and selexipag in patients with pulmonary arterial hypertension (PAH) has never been described in literature. Our aim was to prepare indirect treatment comparison (ITC) to evaluate the cost-effectiveness of riociguat in Czechia. Methods A systematic literature review identified two relevant trials with comparable endpoints to inform a Bucher ITC of relative and absolute effects. Given the comparable efficacy of riociguat and selexipag, a cost-minimization analysis (CMA) was conducted. Results A Bucher ITC provided evidence for the comparable relative efficacy of riociguat defined as the odds of unimproved functional class III 0.761 (95% CI 0.372 to 1.558; p = 0.455) compared to selexipag and a comparable absolute efficacy defined as a difference in the 6-minute walking distance of 10.560 meters (95% CI -10.692 to 31.812; p = 0.330). The CMA identified riociguat as the cost-saving therapy. Conclusions Switching to riociguat represents the cost-saving therapy for PAH patients who were inadequately compensated with the PDE5i+ERA therapy. Consequently, riociguat has been introduced to the list of reimbursed medicines in Czechia from October 2021. Based on two global trials, we prepared the first indirect treatment comparison followed with CMA of these therapies that may improve future decision-making for PAH indications.
ER  -

ORNSTOVA, Eva, Jan TUZIL, Katerina CHADIMOVA, Tomas MLCOCH a Tomáš DOLEŽAL. Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension. \textit{EXPERT REVIEW OF PHARMACOECONOMICS \&{} OUTCOMES RESEARCH}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2022, roč.~22, č.~8, s.~1269-1275. ISSN~1473-7167. Dostupné z: https://dx.doi.org/10.1080/14737167.2022.2126833.

Podrobný výpis o publikaci